Traws Pharma, Inc. annual report, FY2018

Filing identity and reporting period

The supplied filing is Onconova Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed April 1, 2019. It is not identified in the filing as a Traws Pharma filing, and it reports annual—not standalone fourth-quarter—results. Investors should verify the issuer and filing before relying on this summary. Financial figures below are presented in U.S. dollars; share and per-share amounts reflect the company’s one-for-fifteen reverse stock split effective September 25, 2018.

Business context and key financial metrics

Onconova was a clinical-stage biopharmaceutical company focused primarily on rigosertib, including a Phase 3 trial for higher-risk myelodysplastic syndromes (MDS). It had no approved products and generated no commercial product sales; reported revenue came from licensing, collaboration, and product-supply arrangements.

At December 31, 2018, cash and cash equivalents were $16.970 million, working capital was $9.327 million, total assets were $17.923 million, and total liabilities were $12.536 million. Stockholders’ equity was $5.387 million, compared with a deficit of $10.861 million a year earlier. The balance sheet lists no borrowings; it includes a $0.176 million warrant liability. The filing reports no off-balance-sheet arrangements. No meaningful operating margin is reported, given the absence of product sales and ongoing operating losses.

Changes versus the prior year

• Revenue rose $0.441 million, primarily from recognition of HanX and Pint license revenue, partly offset by lower SymBio supply revenue. Revenue remained small relative to operating expenses.
• Operating expenses declined $2.014 million. R&D fell $2.195 million, including lower INSPIRE trial, consulting, manufacturing, and stock-compensation costs; G&A increased $0.181 million.
• Net loss narrowed by $3.682 million. In addition to lower operating expenses, results included $1.151 million of other income, including a gain related to dissolution of the GBO collaboration. The $1.597 million favorable change in warrant fair value also reduced the reported loss.
• Cash increased from $4.024 million to $16.970 million, primarily because financing activities provided $35.657 million, including net proceeds from 2018 equity and warrant offerings. Financing cash more than offset operating cash use.

Outlook, commentary, and risks

• Management estimated that year-end cash would fund ongoing trials and operations into the fourth quarter of 2019, while stating that additional financing was needed. The auditor’s report and management disclosure identify substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements were issued.
• Management expected 2019 net cash expenditures to decline from 2018, citing the status of INSPIRE sites and cost-control efforts. This was an expectation, not a guarantee; the company noted possible additional workforce-reduction costs.
• INSPIRE’s blinded interim analysis led the independent monitoring committee to recommend expanding enrollment by 135 patients, to an expected total of 360, and increasing the targeted death events from 176 to 288. The primary endpoint remains overall survival. The company reported passing 75% enrollment in March 2019 and expected enrollment completion in the second half of 2019; interim efficacy results were not disclosed.
• The company said it would not begin a planned Phase 3 trial of oral rigosertib plus azacitidine, or further development of certain other rigosertib programs, without additional financing. The earlier ONTIME Phase 3 trial did not meet its primary overall-survival endpoint.
• In March 2019, the company announced a six-employee reduction. It estimated a one-time severance charge of approximately $0.7 million and annual savings of approximately $1.5 million, expected to be fully realized during 2020.
• Key risks include financing and dilution, clinical-trial efficacy and enrollment, regulatory approval, dependence on third-party manufacturers and research organizations, intellectual-property protection, competition, and continued Nasdaq listing compliance. The company also reported that briciclib’s IND remained on full clinical hold following a drug-product lot testing failure.

Most important facts for investors to verify

1. Confirm the filing’s issuer: the document names Onconova Therapeutics, Inc., not Traws Pharma, Inc.; also verify any corporate name or successor relationship relevant to the requested company.
2. Check current cash, financing availability, and subsequent filings against the stated fourth-quarter 2019 cash runway and going-concern warning.
3. Verify INSPIRE enrollment, trial status, final enrollment target, event target, and eventual overall-survival results; the filing’s interim results remained blinded.
4. Assess the likelihood and funding requirements of the proposed oral rigosertib Phase 3 program and any other development plans.
5. Review actual post-filing workforce-reduction costs and savings, as well as dilution exposure from outstanding warrants and equity awards.